• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec10
Mizuho Securities Analyst Reiterates Buy Rating for Nurix Therapeutics
13:38
Dec8
Stifel Nicolaus Maintains Buy Rating on Nurix Therapeutics
13:32
Nurix Therapeutics Unveils Phase 1 Trial Data of Bexobrutideg at ASH Annual Meeting
13:07
Nov7
Oppenheimer Reiterates Buy Rating on Nurix Therapeutics
19:56
Nov4
Gil Blum gives Nurix Therapeutics' bexodeg a buy rating
10:16
Oct23
Nurix Therapeutics Maintained at Hold Rating
08:47

Schedules & Filings

Schedules
Filings
Oct9
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 7.894 M, Net Income -86.42 M, EPS -1.0268

Jul9
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 44.06 M, Net Income -43.46 M, EPS -0.5181

Apr8
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 18.45 M, Net Income -56.35 M, EPS -0.6743

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
BBGI
16.690
+312.10%
+12.640
SRV.RT
0.0900
+111.76%
+0.048
BEAT
1.550
+92.43%
+0.745
ENVB
10.330
+74.49%
+4.410
BDRX
6.720
+65.11%
+2.650
ASPC
16.810
+60.40%
+6.330
IRBT
5.240
+48.44%
+1.710
CGTL
0.9727
+47.40%
+0.313
MIGI
6.700
+45.65%
+2.100
PLAB
37.350
+45.39%
+11.660
View More